Quantum Biopharma (QNTM) Other Non-Current Liabilities (2020 - 2026)
Quantum Biopharma (QNTM) reported Other Non-Current Liabilities of $5.3 million for Q1 2026, up 87.19% on a YoY basis from $2.8 million in Q1 2025, and down 31.47% sequentially from $7.8 million in Q2 2025.
Quantum Biopharma (QNTM) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Quantum Biopharma (QNTM) has 7 years of Other Non-Current Liabilities data on file, last reported at $5.3 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 87.19% year-over-year to $5.3 million; the trailing twelve-month figure through Mar 2026 stood at $5.3 million (up 87.19% YoY), and the FY2024 full-year result was $212002.0, changed N/A from the prior year.
- Other Non-Current Liabilities slipped to $5.3 million in Q1 2026, from $7.8 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $7.8 million in Q2 2025 to a low of $1.0 in Q2 2024.
- A 5-year average of $1.4 million and a median of $388481.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities sank 100.0% in 2024 and jumped 776068300.0% in 2025, its largest moves.
- Tracing QNTM's Other Non-Current Liabilities over 5 years: stood at $243594.0 in 2022, then tumbled by 46.48% to $130383.0 in 2023, then soared by 62.6% to $212002.0 in 2024, then soared by 3560.67% to $7.8 million in 2025, then plunged by 31.47% to $5.3 million in 2026.
- Business Quant data shows QNTM's Other Non-Current Liabilities at $5.3 million in Q1 2026, $7.8 million in Q2 2025, and $2.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Quantum Biopharma | 13.00 Bn | 13.00 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.32 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Mar 31, 2025 | 2.84 Mn |
| Dec 31, 2024 | 212,002.00 |
| Sep 30, 2024 | 75.00 |
| Jun 30, 2024 | 1.00 |
| Sep 30, 2023 | 130,383.00 |
| Jun 30, 2023 | 122,351.00 |
| Mar 31, 2023 | 450,544.00 |
| Dec 31, 2022 | 243,594.00 |
| Sep 30, 2022 | 388,481.00 |
| Jun 30, 2022 | 425,620.00 |
| Mar 31, 2022 | 522,884.00 |
| Dec 31, 2021 | 765,403.00 |
| Sep 30, 2021 | 1.43 Mn |
| Jun 30, 2021 | 1.71 Mn |
| Mar 31, 2021 | 2.00 Mn |
| Dec 31, 2020 | 1.45 Mn |
| Sep 30, 2020 | 2.61 Mn |